Table 1 Genotypic frequencies according to clinical parameters of the Moroccan CD patients investigated for the T300A polymorphism
From: IL23R and ATG16L1 variants in Moroccan patients with inflammatory bowel disease
ATG16L1 T300A | P value | Chi-square | ||||
|---|---|---|---|---|---|---|
N | AA | AG | GG | Test | ||
Age of onset | 69 | 0.37 | 4.30 | |||
<17 years | 10 | - | 8 (80.0) | 2 (20.0) | ||
17-40 | 52 | 15 (28.8) | 30 (57.7) | 7 (13.5) | ||
>40 years | 7 | 1 (14.3) | 5 (71.4) | 1 (14.3) | ||
Sex | 69 | 0.57 | 1.14 | |||
Woman | 25 | 4 (16.0) | 17 (68.0) | 4 (16.0) | ||
Man | 44 | 12 (27.3) | 26 (59.1) | 6 (13.6) | ||
Type | 69 | 0.03 | 13.7 | |||
Fistulizing | 26 | 5 (19.2) | 20 (76.9) | 1 (3.8) | ||
Non fistulizing Non stenosing | 24 | 7 (29.2) | 10 (41.7) | 7 (29.2) | ||
Stenosing | 12 | 4 (33.3) | 8 (66.7) | - | ||
Fistulizingstenosing | 7 | - | 5 (71.4) | 2 (28.6) | ||
Localization | 69 | 0.36 | 17.4 | |||
L1 | 19 | 1 (5.3) | 13 (68.4) | 5 (26.3) | ||
L1 + P | 2 | 1 (50.0) | 1 (50.0) | - | ||
L2 | 10 | 4 (40.0) | 4 (40.0) | 2 (20.0) | ||
L2 + P | 7 | 3 (42.9) | 4 (57.1) | - | ||
L3 | 19 | 6 (31.6) | 11 (57.9) | 2 (10.5) | ||
L3 + P | 1 | - | 1 (100.0) | - | ||
L4 | 2 | - | 1 (50.0) | 1 (50.0) | ||
L4 + L2 | 4 | 1 (25.0) | 3 (75.0) | - | ||
P | 5 | - | 5 (100.0) | - | ||
SFC | 69 | 0.09 | 4.8 | |||
Presence | 4 | - | 2 (50.0) | 2 (50.0) | ||
Absence | 65 | 16 (24.6) | 41 (63.1) | 8 (12.3) | ||
Smoking | 69 | 0.96 | 0.1 | |||
Presence | 28 | 7 (25.0) | 17 (60.7) | 4 (14.3) | ||
Absence | 41 | 9 (22.0) | 26 (63.4) | 6 (14.6) | ||
Appendectomy | 69 | 0.22 | 3.1 | |||
Presence | 9 | 2 (22.2) | 4 (44.4) | 3 (33.3) | ||
Absence | 60 | 14 (23.3) | 39 (65.0) | 7 (11.7) | ||
EIM | 69 | 0.97 | 0.1 | |||
Presence | 39 | 9 (23.1) | 24 (61.5) | 6 (15.4) | ||
Absence | 30 | 7 (23.3) | 19 (63.3) | 4 (13.3) | ||
Surgery | 69 | 0.14 | 4.0 | |||
Presence | 29 | 4 (13.8) | 22 (75.9) | 3 (10.3) | ||
Absence | 40 | 12 (30.0) | 21 (52.5) | 7 (17.5) | ||